MARKET

GRFS

GRFS

Grifols
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.44
-0.80
-4.39%
Opening 15:09 08/10 EDT
OPEN
18.30
PREV CLOSE
18.24
HIGH
18.30
LOW
17.34
VOLUME
469.63K
TURNOVER
--
52 WEEK HIGH
25.73
52 WEEK LOW
13.40
MARKET CAP
4.50B
P/E (TTM)
19.14
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GRFS stock price target is 26.75 with a high estimate of 26.75 and a low estimate of 26.75.

EPS

GRFS News

More
Convalescent Plasma Found to Reduce COVID-19 Death Rate in New Study
The results provide more justification for the FDA to grant the substance emergency use authorization.
Motley Fool · 4d ago
Rigel Pharmaceuticals Inc (RIGL) Q2 2020 Earnings Call Transcript
It is now my pleasure to introduce our first speaker Dolly Vance, who is Rigel's Executive Vice President, Corporate Affairs and General Counsel. As a reminder, during today's call we may make forward-looking statements regarding our financial outlook and our
Motley Fool · 5d ago
Grifols delivers first batch of hyperimmune globulin for COVID-19 studies
Seeking Alpha · 07/28 15:22
Grifols delivers first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced it has delivered the fi
PR Newswire · 07/28 14:41
Grifols Says Delivers First Manufactured Batches of Anti-Sars-Cov-2 Hyperimmune Globulin For Clinical Trial
-Reuters
Reuters · 07/28 13:44
Grifols Shares Spike Higher After Results Of Grifols' AMBAR Clinical Trial Published In Alzheimer's & Dementia Publication
Benzinga · 07/27 17:03
Grifols makes investment in digital healthcare space
Grifols (NASDAQ:GRFS) has acquired 10% of Bloodbuy, a cloud-based marketplace that facilitates buying and selling of blood components in the U.S. Grifols m
seekingalpha · 07/23 17:50
Grifols Reports Purchase Of 10% Stake Of Bloodbuy, No Terms Disclosed
Benzinga · 07/23 12:02

Industry

Pharmaceuticals
+0.10%
Pharmaceuticals & Medical Research
+0.13%

Hot Stocks

Symbol
Price
%Change

About GRFS

Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma for therapeutic use. The Hospital division offers non-biological pharmaceutical products and medical supplies for hospital pharmacy. The Diagnostic division provides clinical analysis and laboratory testing tools to laboratories, hospitals and blood banks. The Raw materials division includes sales of intermediate biological products, as well as manufacturing services to third parties. The Company operates production facilities in Spain, the United States, Mexico and Australia, among others. It controls numerous subsidiaries, such as Kiro Grifols SL.
More

Webull offers kinds of Grifols SA - ADR stock information, including NASDAQ:GRFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRFS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRFS stock methods without spending real money on the virtual paper trading platform.